Drilldown: Medicines
Medicines > classes 
:
Antidepressant or
Neuroleptic or
[[:Category:Psychostimulants|Psychostimulant]] (atypical)
:
Antidepressant or
Neuroleptic or
[[:Category:Psychostimulants|Psychostimulant]] (atypical) Use the filters below to narrow your results.
generic:
Agomelatine (1) ·
Amoxapine (1) ·
Asenapine (1) ·
Chlorpromazine (1) ·
Clomipramine (1) ·
Desipramine (1) ·
Droperidol (1) ·
Duloxetine (1) ·
Fluphenazine (1) ·
Iloperidone (1) ·
Imipramine (1) ·
Isocarboxazid (1) ·
Levomilnacipran (1) ·
Loxapine (1) ·
Lurasidone (1) ·
Maprotiline (1) ·
Milnacipran (1) ·
Moclobemide (1) ·
Modafinil (1) ·
Molindone (1) ·
Nefazodone (1) ·
Paliperidone (1) ·
Perphenazine (1) ·
Phenelzine (1) ·
Pimozide (1) ·
Protriptyline (1) ·
Reboxetine (1) ·
Sertraline (1) ·
Thioridazine (1) ·
Thiothixene (1) ·
Tianeptine (1) ·
Tranylcypromine (1) ·
Trifluoperazine (1) ·
Trimipramine (1) ·
Ziprasidone (1)
brand:
None (1) ·
Anafranil (1) ·
Aurorix (1) ·
Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1) ·
Edronax (1) ·
Fanapt (1) ·
Fetzima (1) ·
Geodon (1) ·
Inapsine (1) ·
Invega (1) ·
Latuda (1) ·
Loxitane (1) ·
Ludiomil (1) ·
Marplan (1) ·
Mellaril (1) ·
Moban (1) ·
Nardil (1) ·
Navane (1) ·
Norpramin (1) ·
Orap (1) ·
Parnate (1) ·
Prolixin (1) ·
Provigil (Teva/Cephalon); Alertec (Canada); Modavigil (Australia) (1) ·
Saphris (1) ·
Savella (1) ·
Serzone (1) ·
Stablon (1) ·
Stelazine (1) ·
Surmontil (1) ·
Thorazine (1) ·
Tofranil (1) ·
Trilafon (1) ·
Valdoxan (1) ·
Vivactil (1) ·
Zoloft (1)
classes: (Click arrow to add another value)
mechanism:
None (1) ·
Butyrophenone D2 antagonist (1) ·
D2 receptor antagonist; also H1, alpha-1, muscarinic antagonist (1) ·
D2/5-HT2A antagonist (1) ·
D2/5-HT2A antagonist; 5-HT7 antagonist (1) ·
D2/5-HT2A antagonist; active metabolite of risperidone (1) ·
D2/5-HT2A antagonist; SRI and NRI (1) ·
Dibenzoxazepine D2/5-HT2 antagonist (1) ·
Dihydroindolone D2 antagonist (1) ·
Diphenylbutylpiperidine D2 antagonist (1) ·
Irreversible non-selective MAO inhibitor (3) ·
Melatonin receptor agonist; 5-HT2C antagonist (1) ·
Mu-opioid agonist; modulates glutamate AMPA receptors (1) ·
Multi-receptor antagonist (D2, 5-HT2A, H1, alpha) (1) ·
Phenothiazine D2 antagonist (4) ·
Potent serotonin reuptake inhibitor; also NRI (1) ·
Reversible inhibitor of MAO-A (1) ·
Selective norepinephrine reuptake inhibitor (3) ·
Serotonin and norepinephrine reuptake inhibitor (3) ·
Serotonin reuptake inhibitor and 5-HT2A antagonist (1) ·
Serotonin–norepinephrine reuptake inhibition (balanced) (1) ·
Serotonin–norepinephrine reuptake inhibitor (2) ·
Thioxanthene D2 antagonist (1) ·
TrkB/BDNF'"`UNIQ--ref-00000084-QINU`"' '"`UNIQ--vote-00000085-QINU`"' (1) ·
Weak SRI; primarily H1/D2/alpha antagonist (1)
uses:
preparations:
onset:
None (32) ·
Anxiolysis classically 3-4 weeks, continuing improvement to 8-12 weeks (1) ·
Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1) ·
Peak plasma concentration in 2-4 hours after oral administration. Clinically perceptible wakefulness-promoting effects typically begin within 1-2 hours of dosing.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
duration:
None (32) ·
Chronic daily dosing (1) ·
Effective duration approximately 12-15 hours at the 200 mg dose, consistent with the elimination half-life. A single morning dose generally sustains wakefulness throughout the day without substantially disrupting nighttime sleep onset when taken early.'"`UNIQ--ref-0000006D-QINU`"' (1) ·
Long (1)
halflife:
bioavailability:
None (32) ·
Absolute bioavailability not precisely characterized; food modestly increases exposure (1) ·
Oral bioavailability is not precisely established in the label but absorption is rapid and essentially complete. Food delays peak plasma concentration by approximately one hour but does not reduce the extent of absorption.'"`UNIQ--ref-0000006F-QINU`"' (1) ·
~50% (highly variable) (1)
pregnancy:
legal:
Showing below up to 35 results in range #1 to #35.